Avidity Biosciences Inc., a biopharmaceutical company focused on RNA therapeutics, announced new inducement grants under its 2022 Employment Inducement Incentive Award Plan. On May 20, 2025, the company's Human Capital Management Committee granted non-qualified stock option awards for 71,000 shares and 35,000 restricted stock units (RSUs) to sixteen new non-executive employees. These inducement awards are part of the company's efforts to attract new talent and are issued in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $31.64 per share, matching the closing price of Avidity's stock on the Nasdaq Global Market on the grant date. The options and RSUs will vest over four years, contingent upon the employees' continued employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.